{
    "id": 23893,
    "fullName": "ERBB3 V714M",
    "impact": "missense",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) V714M lies within the protein kinase domain of the Erbb3 (Her3) protein (UniProt.org). V714M demonstrates growth promotion and transforming ability in the presence of Erbb2 (Her2) similar to wild-type Erbb3 (Her3) in culture (PMID: 23680147).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "V714M",
    "createDate": "06/29/2016",
    "updateDate": "06/29/2016",
    "referenceTranscriptCoordinates": {
        "id": 123527,
        "transcript": "NM_001982",
        "gDna": "chr12:g.56096587G>A",
        "cDna": "c.2140G>A",
        "protein": "p.V714M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11951,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Perjeta (pertuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V714M in culture (PMID: 23680147).",
            "molecularProfile": {
                "id": 24618,
                "profileName": "ERBB3 V714M"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11952,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V714M in culture (PMID: 23680147).",
            "molecularProfile": {
                "id": 24618,
                "profileName": "ERBB3 V714M"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11950,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) V714M in culture (PMID: 23680147).",
            "molecularProfile": {
                "id": 24618,
                "profileName": "ERBB3 V714M"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24618,
            "profileName": "ERBB3 V714M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123527,
            "transcript": "NM_001982",
            "gDna": "chr12:g.56096587G>A",
            "cDna": "c.2140G>A",
            "protein": "p.V714M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}